Pub Date : 2023-10-20DOI: 10.26420/austinjmedoncol.2023.1075
Yinglin Bao, Feng Liu, Qing Xia, Qingxia Luan, Albandri Bin Ammar, Nessar Ahmed, M. Slevin, Kamela Ali, Donghui Liu
Impaired wound healing is associated with hyperglycaemia in patients with diabetes. Hyperglycaemia induces protein glycation and the formation of Advanced Glycation End-Products (AGEs). The accumulation of AGEs in the body results in the structural and functional modification of tissue proteins. This study was conducted to evaluate compounds with antiglycation activities (S-Ally1 Cysteine (SAC), N-Acetylcysteine (NAC) and the mimic compound A). The extent of glycation in the presence and absence of several inhibitors was assessed via several methods including fluorescence, Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)- silver stain, Western blotting, and Enzyme-Linked Immunosorbent Assays (ELISA). Additionally, this research aimed to evaluate and quantify the potential of Human Adipose Mesenchymal Stem Cells (hADMSCs) to uptake and release these drugs as potential therapeutics. To achieve this, hADMSCs were primed with a combination of SAC/NAC and mimic compound A and their concentrations were analysed using High-Performance Liquid Chromatography (HPLC). The SAC/NAC and mimic compound A prohibit the formation of AGEs while the Conditioned Medium (CM) from SAC/NACand compound A-loaded hADMSCs induced cell migration and tube formation in BAECs. hADMSCs provide a unique opportunity for the development of an innovative targeting and drug-delivery system which could effectively deliver therapeutics to specific regions of wounds or other damaged tissues. The data provided demonstrate the potential of hADMSCs as a drug delivery method with the potential to improve wound healing, and it may offer potential therapeutic targeting for the development of diabetic complications.
{"title":"Innovative Wound Dressing Coated with Drug-Loaded Adipose Mesenchymal Stem Cells to Promote Wound Healing in Diabetes","authors":"Yinglin Bao, Feng Liu, Qing Xia, Qingxia Luan, Albandri Bin Ammar, Nessar Ahmed, M. Slevin, Kamela Ali, Donghui Liu","doi":"10.26420/austinjmedoncol.2023.1075","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2023.1075","url":null,"abstract":"Impaired wound healing is associated with hyperglycaemia in patients with diabetes. Hyperglycaemia induces protein glycation and the formation of Advanced Glycation End-Products (AGEs). The accumulation of AGEs in the body results in the structural and functional modification of tissue proteins. This study was conducted to evaluate compounds with antiglycation activities (S-Ally1 Cysteine (SAC), N-Acetylcysteine (NAC) and the mimic compound A). The extent of glycation in the presence and absence of several inhibitors was assessed via several methods including fluorescence, Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)- silver stain, Western blotting, and Enzyme-Linked Immunosorbent Assays (ELISA). Additionally, this research aimed to evaluate and quantify the potential of Human Adipose Mesenchymal Stem Cells (hADMSCs) to uptake and release these drugs as potential therapeutics. To achieve this, hADMSCs were primed with a combination of SAC/NAC and mimic compound A and their concentrations were analysed using High-Performance Liquid Chromatography (HPLC). The SAC/NAC and mimic compound A prohibit the formation of AGEs while the Conditioned Medium (CM) from SAC/NACand compound A-loaded hADMSCs induced cell migration and tube formation in BAECs. hADMSCs provide a unique opportunity for the development of an innovative targeting and drug-delivery system which could effectively deliver therapeutics to specific regions of wounds or other damaged tissues. The data provided demonstrate the potential of hADMSCs as a drug delivery method with the potential to improve wound healing, and it may offer potential therapeutic targeting for the development of diabetic complications.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139316427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-28DOI: 10.26420/austinjmedoncol.2022.1073
Selim M. Khan
Application of Deep Learning LSTM and ARIMA Models in Time Series Forecasting: A Methods Case Study analyzing Canadian and Swedish Indoor Air Pollution Data
深度学习LSTM和ARIMA模型在时间序列预测中的应用——以加拿大和瑞典室内空气污染数据为例
{"title":"Application of Deep Learning LSTM and ARIMA Models in Time Series Forecasting: A Methods Case Study analyzing Canadian and Swedish Indoor Air Pollution Data","authors":"Selim M. Khan","doi":"10.26420/austinjmedoncol.2022.1073","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2022.1073","url":null,"abstract":"Application of Deep Learning LSTM and ARIMA Models in Time Series Forecasting: A Methods Case Study analyzing Canadian and Swedish Indoor Air Pollution Data","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"282 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76809174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.26420/austinjmedoncol.2022.1072
Meng Yb, Cheng Sm, Y. M, Xu Xw, C. L, Zhu Xj, Du J
Objective: Dexamethasone (DEX) is considered an effective treatment for Post-Embolization Syndrome (PES). However, the current commonly used DEX treatment course is long and involves a large amount of DEX and thus causes substantial side effects. This study aimed to evaluate the efficacy and safety of low-dose shortcourse DEX treatment in the prevention of PES to establish a new treatment course. Methods: A retrospective cohort study was conducted to observe the efficacy of DEX in treating PES on patients with primary liver cancer who underwent Transcatheter Arterial Chemoembolization (TACE). DEX was selected according to the wishes of the patients, who were subsequently divided into two groups. In the experimental group, 52 patients daily received an intravenous injection of 5 mg DEX and 5 mg tropisetron, starting on the day of TACE. The remaining 52 patients (control group) were treated with only 5 mg tropisetron daily. Incidence and degree of vomiting, abdominal pain, and fever were recorded. Routine blood tests and the C-Reactive Protein (CRP) test were performed, liver and kidney functions were evaluated, and the coagulation index and Eastern Cooperative Oncology Group (ECOG) performance status were assessed before and after TACE. Results: Severity scores of adverse reactions, such as vomiting, fever, and abdominal pain; incidence of grade 2 and 3 adverse reactions; and CRP and ECOG scores were significantly lower in the experimental group than in the control group (P< 0.05). There was no significant difference in routine blood parameters, liver and kidney functions, or coagulation between the two groups before or after TACE (P> 0.05). Conclusion: Low-dose and short-course DEX treatment after TACE can effectively reduce the severity of PES without side effects.
{"title":"Low-Dose and Short-Course Dexamethasone Treatment as a New Therapy against the Post-Embolization Syndrome after Transcatheter Arterial Chemoembolization in Primary Liver Cancer: A Retrospective Case-Control Study","authors":"Meng Yb, Cheng Sm, Y. M, Xu Xw, C. L, Zhu Xj, Du J","doi":"10.26420/austinjmedoncol.2022.1072","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2022.1072","url":null,"abstract":"Objective: Dexamethasone (DEX) is considered an effective treatment for Post-Embolization Syndrome (PES). However, the current commonly used DEX treatment course is long and involves a large amount of DEX and thus causes substantial side effects. This study aimed to evaluate the efficacy and safety of low-dose shortcourse DEX treatment in the prevention of PES to establish a new treatment course. Methods: A retrospective cohort study was conducted to observe the efficacy of DEX in treating PES on patients with primary liver cancer who underwent Transcatheter Arterial Chemoembolization (TACE). DEX was selected according to the wishes of the patients, who were subsequently divided into two groups. In the experimental group, 52 patients daily received an intravenous injection of 5 mg DEX and 5 mg tropisetron, starting on the day of TACE. The remaining 52 patients (control group) were treated with only 5 mg tropisetron daily. Incidence and degree of vomiting, abdominal pain, and fever were recorded. Routine blood tests and the C-Reactive Protein (CRP) test were performed, liver and kidney functions were evaluated, and the coagulation index and Eastern Cooperative Oncology Group (ECOG) performance status were assessed before and after TACE. Results: Severity scores of adverse reactions, such as vomiting, fever, and abdominal pain; incidence of grade 2 and 3 adverse reactions; and CRP and ECOG scores were significantly lower in the experimental group than in the control group (P< 0.05). There was no significant difference in routine blood parameters, liver and kidney functions, or coagulation between the two groups before or after TACE (P> 0.05). Conclusion: Low-dose and short-course DEX treatment after TACE can effectively reduce the severity of PES without side effects.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83385598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-15DOI: 10.26420/austinjmedoncol.2022.1070
Pattnaik J, Paramanandhan M, Madasamy P, Kayal S, S. J, Jadhav N
Thrombocytopenia is a commonly encountered during course of chemotherapy. Breast cancer is the most common cancer in women worldwide. A 58 years old lady, diagnosed case of carcinoma breast left side (early stage) on adjuvant trastuzumab therapy developed progressive thrombocytopenia. The treatment was stopped and started on oral steroids. The platelet count recovered slowly on oral steroids. In this review we have highlighted a very rarely encountered side effect of trastuzumab induced thrombocytopenia.
{"title":"Trastuzumab Induced Thrombocytopenia in Early Breast Cancer: Case Report and Review of Literature","authors":"Pattnaik J, Paramanandhan M, Madasamy P, Kayal S, S. J, Jadhav N","doi":"10.26420/austinjmedoncol.2022.1070","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2022.1070","url":null,"abstract":"Thrombocytopenia is a commonly encountered during course of chemotherapy. Breast cancer is the most common cancer in women worldwide. A 58 years old lady, diagnosed case of carcinoma breast left side (early stage) on adjuvant trastuzumab therapy developed progressive thrombocytopenia. The treatment was stopped and started on oral steroids. The platelet count recovered slowly on oral steroids. In this review we have highlighted a very rarely encountered side effect of trastuzumab induced thrombocytopenia.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87243171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.26420/austinjmedoncol.2021.1069
Wawrzyniak P, H. A., Heinze S, Bobek-Billewicz B
Purpose: ¹H-Magnetic Resonance Spectroscopy is a non-invasive technique that provides information on tissue metabolism and biochemistry. Because of technical difficulties, this method is rarely used in the spinal cord examination. The main goal of this study was to develop a routine protocol for MRS of intramedullary lesions. Material and methods: ¹H-MRS protocol was set on a group of healthy volunteers. 48 spectra were acquired in total. 30 of them were acquired in cervical spinal cord and the remaining (18 spectra) were acquired in the thoracic spinal cord. Results: In ¹H-MRS of the spinal cord one of the most important problem is small voxel size. Mean voxel size in this study was 7x9x29 mm - what is much smaller than in the brain examinations finally, almost 60% of spectra were of acceptable quality in volunteer examinations, what enabled the following patients’ examinations. Conclusions: Challenges of spinal cord spectroscopy were discussed and the ability of providing additional diagnostic information was proved.
{"title":"Single Voxel ¹H-MR Spectroscopy in the Human Spinal Cord at 3T -Preliminary Results","authors":"Wawrzyniak P, H. A., Heinze S, Bobek-Billewicz B","doi":"10.26420/austinjmedoncol.2021.1069","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2021.1069","url":null,"abstract":"Purpose: ¹H-Magnetic Resonance Spectroscopy is a non-invasive technique that provides information on tissue metabolism and biochemistry. Because of technical difficulties, this method is rarely used in the spinal cord examination. The main goal of this study was to develop a routine protocol for MRS of intramedullary lesions. Material and methods: ¹H-MRS protocol was set on a group of healthy volunteers. 48 spectra were acquired in total. 30 of them were acquired in cervical spinal cord and the remaining (18 spectra) were acquired in the thoracic spinal cord. Results: In ¹H-MRS of the spinal cord one of the most important problem is small voxel size. Mean voxel size in this study was 7x9x29 mm - what is much smaller than in the brain examinations finally, almost 60% of spectra were of acceptable quality in volunteer examinations, what enabled the following patients’ examinations. Conclusions: Challenges of spinal cord spectroscopy were discussed and the ability of providing additional diagnostic information was proved.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75284746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-10DOI: 10.26420/austinjmedoncol.2021.1068
Nawaz Af, R. A., Iqbal A, Arshad R, Shoukat S, Z. A.
Nanomaterials owing to their remarkable pharmaceutical properties and potential to load large quantities of drugs are considered an ideal vector for carrying medicine to the target site. The treatment of breast cancer has been a pressing issue due the use of conventional methods of treatment resulting in many side effects. Nanotechnology offers a more targeted approach in breast cancer treatment. The present review examines the role of Carbon Nanotubes (CNTs) and nanoparticles in the treatment of breast cancer and the obstacles in the way of nanotechnology in becoming one of the best methods in breast cancer treatment and drug delivery. Use of monoclonal antibody trastuzumab against HER-2 biomarkers by attaching it with nanotubes or nanoparticles is considered the best-targeted therapy along with photo thermal ablation. The absence of human tumor models and lack of toxicological assays are the major factors contributing to differences between the preclinical and clinical trial results.
{"title":"Nanotechnology to Cure Breast Cancer and Obstacles in its Way","authors":"Nawaz Af, R. A., Iqbal A, Arshad R, Shoukat S, Z. A.","doi":"10.26420/austinjmedoncol.2021.1068","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2021.1068","url":null,"abstract":"Nanomaterials owing to their remarkable pharmaceutical properties and potential to load large quantities of drugs are considered an ideal vector for carrying medicine to the target site. The treatment of breast cancer has been a pressing issue due the use of conventional methods of treatment resulting in many side effects. Nanotechnology offers a more targeted approach in breast cancer treatment. The present review examines the role of Carbon Nanotubes (CNTs) and nanoparticles in the treatment of breast cancer and the obstacles in the way of nanotechnology in becoming one of the best methods in breast cancer treatment and drug delivery. Use of monoclonal antibody trastuzumab against HER-2 biomarkers by attaching it with nanotubes or nanoparticles is considered the best-targeted therapy along with photo thermal ablation. The absence of human tumor models and lack of toxicological assays are the major factors contributing to differences between the preclinical and clinical trial results.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"144 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80525559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-27DOI: 10.26420/austinjmedoncol.2021.1067
Lee Em
Background: The first-line combination chemotherapy regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, improved survival outcomes in patients with advanced pancreatic cancer. However, there is no consensus therapy after failure of first-line chemotherapy. This objective of this study was to analysis of the clinical characteristics and outcomes of subsequent chemotherapy in patients who failed first-line FOLFIRINOX. Methods: This retrospective study analyzed the clinical data of patients with advanced pancreatic cancer receiving second-line chemotherapy after failure of FOLFIRINOX at Kosin University Gaspel Hospital from January 2013 to July 2020. Results: Sixty-three patients with advanced pancreatic cancer received first-line FOLFIRINOX, and 33 (51.7%) of those patients received at least one cycle of second-line chemotherapy. At the start of second-line chemotherapy, the median age of patients was 59 years (range, 31-79), and 54.5% (61 patients) was male. The second-line chemotherapy regimens included gemcitabine/ nab-paclitaxel (21, 63.6%), gemcitabine/erlotinib (6, 18.2%), and gemcitabine monotherapy (6, 18.2%). Of twenty-five patients who had measurable disease, only 1 patient (4.0%) achieved a partial response, and the disease control rate was 56% (14 patients). The median Overall Survival (OS) was 8.7 months (95% Confidence Interval [CI], 5.2-12.2), and the median progression-free survival was 3.2 months (95% CI, 1.7-4.8). The median OS from starting FOLFIRINOX was14.7 months (95% CI, 10.4-18.3). There was no significant difference of median OS between second-line regimens. Conclusion: Gemcitabine-based chemotherapy had modest survival benefits in patients with advanced pancreatic cancer after failure of FOLFIRINOX.
{"title":"Second Line Chemotherapy in Patients with Advanced Pancreatic Cancer after Failure of First-Line FOLFIRINOX: A Retrospective Analysis","authors":"Lee Em","doi":"10.26420/austinjmedoncol.2021.1067","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2021.1067","url":null,"abstract":"Background: The first-line combination chemotherapy regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, improved survival outcomes in patients with advanced pancreatic cancer. However, there is no consensus therapy after failure of first-line chemotherapy. This objective of this study was to analysis of the clinical characteristics and outcomes of subsequent chemotherapy in patients who failed first-line FOLFIRINOX. Methods: This retrospective study analyzed the clinical data of patients with advanced pancreatic cancer receiving second-line chemotherapy after failure of FOLFIRINOX at Kosin University Gaspel Hospital from January 2013 to July 2020. Results: Sixty-three patients with advanced pancreatic cancer received first-line FOLFIRINOX, and 33 (51.7%) of those patients received at least one cycle of second-line chemotherapy. At the start of second-line chemotherapy, the median age of patients was 59 years (range, 31-79), and 54.5% (61 patients) was male. The second-line chemotherapy regimens included gemcitabine/ nab-paclitaxel (21, 63.6%), gemcitabine/erlotinib (6, 18.2%), and gemcitabine monotherapy (6, 18.2%). Of twenty-five patients who had measurable disease, only 1 patient (4.0%) achieved a partial response, and the disease control rate was 56% (14 patients). The median Overall Survival (OS) was 8.7 months (95% Confidence Interval [CI], 5.2-12.2), and the median progression-free survival was 3.2 months (95% CI, 1.7-4.8). The median OS from starting FOLFIRINOX was14.7 months (95% CI, 10.4-18.3). There was no significant difference of median OS between second-line regimens. Conclusion: Gemcitabine-based chemotherapy had modest survival benefits in patients with advanced pancreatic cancer after failure of FOLFIRINOX.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"94 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80685196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-06DOI: 10.26420/austinjmedoncol.2021.1066
Jbali S, Ksontini Fl, Dhambri S, Chelly B, M. A., Gritli S
This is a case report of a CIC-rearranged sarcoma located in the neck. Our patient was a 36 year-old-woman with unremarkable past medical history who presented with a left lateralized neck mass evolving for one year without other signs. The physical examination showed a bulky left cervical mass of 12cm long axis, with infected and necrotic areas. There was no palpable lymph nodes. A computed tomography (CT) scan was performed and confirmed the suspicious nature of the lesion and did not show distant metastasis. Histology (completed with Fluorescence in situ Hybridization (FISH) analysis) of a biopsy confirmed the diagnosis of round cell sarcoma with CIC rearrangement. As the tumor was unresectable, we started with chemotherapy but the tumor progressed after three cycles. The patient could not receive a second line chemotherapy because of the deterioration of the general condition and died after 1 month. In conclusion, CIC-rearranged sarcoma is a rare tumor and has a poorer prognosis than the classic Ewing Sarcoma (ES). Its treatment is still challenging. More research is needed to establish the optimal treatment strategies.
{"title":"A Primary Capicua Transcriptional Repressor (CIC)-Rearranged Round Cell Sarcoma of the Neck: A Case Report and Literature Review","authors":"Jbali S, Ksontini Fl, Dhambri S, Chelly B, M. A., Gritli S","doi":"10.26420/austinjmedoncol.2021.1066","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2021.1066","url":null,"abstract":"This is a case report of a CIC-rearranged sarcoma located in the neck. Our patient was a 36 year-old-woman with unremarkable past medical history who presented with a left lateralized neck mass evolving for one year without other signs. The physical examination showed a bulky left cervical mass of 12cm long axis, with infected and necrotic areas. There was no palpable lymph nodes. A computed tomography (CT) scan was performed and confirmed the suspicious nature of the lesion and did not show distant metastasis. Histology (completed with Fluorescence in situ Hybridization (FISH) analysis) of a biopsy confirmed the diagnosis of round cell sarcoma with CIC rearrangement. As the tumor was unresectable, we started with chemotherapy but the tumor progressed after three cycles. The patient could not receive a second line chemotherapy because of the deterioration of the general condition and died after 1 month. In conclusion, CIC-rearranged sarcoma is a rare tumor and has a poorer prognosis than the classic Ewing Sarcoma (ES). Its treatment is still challenging. More research is needed to establish the optimal treatment strategies.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87394163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-30DOI: 10.26420/austinjmedoncol.2021.1065
S. Kamaraju, M. Mohan, T. Wright, J. Charlson, W. Wiger, J. Kwarteng, A. Rezazadeh, L. Hammons, S. Power
Solid tumor oncology treatments are primarily performed in the outpatient setting. However, hospitalizations are inevitable due to complications of cancer and treatment-related toxicities. With rising health care spending, the length of hospital stay (LOS) is increasingly considered a proxy for healthcare costs. There are several ongoing efforts to abbreviate the inpatient LOS and ensure a safe and timely discharge to the outpatient setting. In addition to the acute illness and the associated comorbidities, various factors affect the LOS: social determinants of health, nutritional status in cancer patients, and endof- life issues. Furthermore, it is unclear how the institutional policies on social distancing and visitation during the current coronavirus disease (COVID-19) pandemic may impact the LOS. The purpose of this article is to review various factors and barriers that lead to longer LOS for solid tumor patients during the COVID 19 pandemic, and identify the critical areas of quality improvement.
{"title":"Addressing the Disparities and the Factors Related to Prolonged Inpatient Length of Stay for Solid Tumor Oncology Patients during the COVID-19 Pandemic: A Narrative Review","authors":"S. Kamaraju, M. Mohan, T. Wright, J. Charlson, W. Wiger, J. Kwarteng, A. Rezazadeh, L. Hammons, S. Power","doi":"10.26420/austinjmedoncol.2021.1065","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2021.1065","url":null,"abstract":"Solid tumor oncology treatments are primarily performed in the outpatient setting. However, hospitalizations are inevitable due to complications of cancer and treatment-related toxicities. With rising health care spending, the length of hospital stay (LOS) is increasingly considered a proxy for healthcare costs. There are several ongoing efforts to abbreviate the inpatient LOS and ensure a safe and timely discharge to the outpatient setting. In addition to the acute illness and the associated comorbidities, various factors affect the LOS: social determinants of health, nutritional status in cancer patients, and endof- life issues. Furthermore, it is unclear how the institutional policies on social distancing and visitation during the current coronavirus disease (COVID-19) pandemic may impact the LOS. The purpose of this article is to review various factors and barriers that lead to longer LOS for solid tumor patients during the COVID 19 pandemic, and identify the critical areas of quality improvement.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91151117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-23DOI: 10.26420/austinjmedoncol.2021.1064
M DeOrnelas, Mihaylov Ib
Purpose: To determine the sensitivity of changes to IMRT delivery parameters for mass-based optimization schemes: Dose-Mass- (DM) and Energy-based (Energy), compared to Dose-Volume-based (DV) optimization. Methods: Twelve Head-and-Neck (HN) and twelve lung cases were retrospectively optimized using DM and Energy optimization. In both optimization approaches nine equidistant, split beams were used for step-and-shoot deliverable IMRT. Changes to two parameters were investigated: the number of IMRT segments (5 and 10 per beam) and the minimum allowed segment area (2 and 6 cm²). Plans were normalized such that 95% of the PTV received the same dose. Dose Indices (DIs) were used for evaluation. For the lung cases, DIs included: 1%_cord, 33%_heart, 20% and 30%_both-lungs, and 50%_ esophagus. In the HN cases: 1%_cord, 1%_brainstem, left/right parotids_50%, 50%_larynx, and 50%_esophagus. Results: The lung cases demonstrated that the Energy plans were more sensitive to segment area; changing the segment area resulted in a statistically significant dose increase for 1%_cord, 30%_both-lungs and 50%_esophagus. Changes to the number of segments yielded on average statistically significant differences in dose to 1%_cord in Energy plans, 50%_esophagus in DM plans, and 20%_both-lungs in DV plans. When the segment area was changed, the HN cases yielded statistically significant differences in doses to 1%_cord, 1%_ brainstem, 50%_left and right parotids, and 50%_larynx for the Energy plans and 50%_larynx for DM plans. Moreover, changing the number of segments resulted in significant dose decrease for 50%_parotids and 50%_esophagus for the Energy plans and 50%_larynx for DV plans. Conclusions: This study showed that both lung and HN Energy plans exhibit larger sensitivity than DV and DM plans to changing IMRT delivery parameters, especially when increasing the minimum segment area rather than with varying the number of segments.
{"title":"How Sensitive is Mass-Based Inverse Optimization to IMRT Delivery Parameters?","authors":"M DeOrnelas, Mihaylov Ib","doi":"10.26420/austinjmedoncol.2021.1064","DOIUrl":"https://doi.org/10.26420/austinjmedoncol.2021.1064","url":null,"abstract":"Purpose: To determine the sensitivity of changes to IMRT delivery parameters for mass-based optimization schemes: Dose-Mass- (DM) and Energy-based (Energy), compared to Dose-Volume-based (DV) optimization. Methods: Twelve Head-and-Neck (HN) and twelve lung cases were retrospectively optimized using DM and Energy optimization. In both optimization approaches nine equidistant, split beams were used for step-and-shoot deliverable IMRT. Changes to two parameters were investigated: the number of IMRT segments (5 and 10 per beam) and the minimum allowed segment area (2 and 6 cm²). Plans were normalized such that 95% of the PTV received the same dose. Dose Indices (DIs) were used for evaluation. For the lung cases, DIs included: 1%_cord, 33%_heart, 20% and 30%_both-lungs, and 50%_ esophagus. In the HN cases: 1%_cord, 1%_brainstem, left/right parotids_50%, 50%_larynx, and 50%_esophagus. Results: The lung cases demonstrated that the Energy plans were more sensitive to segment area; changing the segment area resulted in a statistically significant dose increase for 1%_cord, 30%_both-lungs and 50%_esophagus. Changes to the number of segments yielded on average statistically significant differences in dose to 1%_cord in Energy plans, 50%_esophagus in DM plans, and 20%_both-lungs in DV plans. When the segment area was changed, the HN cases yielded statistically significant differences in doses to 1%_cord, 1%_ brainstem, 50%_left and right parotids, and 50%_larynx for the Energy plans and 50%_larynx for DM plans. Moreover, changing the number of segments resulted in significant dose decrease for 50%_parotids and 50%_esophagus for the Energy plans and 50%_larynx for DV plans. Conclusions: This study showed that both lung and HN Energy plans exhibit larger sensitivity than DV and DM plans to changing IMRT delivery parameters, especially when increasing the minimum segment area rather than with varying the number of segments.","PeriodicalId":8626,"journal":{"name":"Austin journal of medical oncology","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74434502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：